

Financial Highlights*

	2002	2001	Change	2002
	in € m	in € m	in %	in U.S. \$ ³ m
Net sales	4,325	4,777	-9	4,535
EBITDA ¹ excluding special charges	440	398	11	461
Special charges	1	(496)	n.m.	1
Operating profit (loss)	155	(488)	n.m.	162
Profit (loss) before taxes	166	(490)	n.m.	173
Net earnings (loss):				
continuing operations	113	(364)	n.m.	117
continuing and discontinued operations	187	(385)	n.m.	195
Capital expenditures on property,				
plant and equipment	(218)	(217)	n.m.	(229)
Average shares outstanding (thousands)	50,329	50,332	n.m.	50,329
Earnings (loss) per share (in €, US \$):				
continuing operations	2.25	(7.23)	n.m.	2.32
continuing and discontinued operations	3.72	(7.65)	n.m.	3.87
in € million as of December 31				
Net financial debt ²	497	835	-40	521
Shareholders' equity	2,005	2,210	-9	2,102
Total assets	6,127	7,064	-13	6,424
Number of employees year-end	10,700	10,750	n.m.	10,700

* All financial data has been restated to reflect the divestiture of the Trespaphan oriented polypropylene (OPP) films (formerly in the Performance Products segment) and U.S. amines (formerly in the Chemical Intermediates segment) businesses, which are included in discontinued operations. The number of employees includes the newly acquired Emulsions business.

¹ Earnings before interest, taxes, depreciation and amortization

² Short- and long-term debt less cash and cash equivalents

³ All dollar figures translated solely for the convenience of the reader at the year-end exchange rate US \$ 1.0485 per euro

n.m. = not meaningful